COMPOUNDS AND THEIR USES FOR ALLEVIATING MENOPAUSE-ASSOCIATED SYMPTOMS
The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at a specific daily dose, optionally in combination with a progestogenic component. The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.
1 - 15 . (canceled)
16 . A method of treating moderate to severe vasomotor symptoms (VMS) associated with menopause, comprising administering once daily a composition comprising about 15 mg estetrol.
17 . The method of claim 16 , further comprising administering a progestogenic component.
18 . The method of claim 17 , wherein said progestogenic component is selected from drospirenone, progesterone, and dydrogesterone.
19 . The method of claim 17 , wherein said progestogenic component is progesterone and is administered at a daily dose of from 50 mg to 200 mg.
20 . The method of claim 17 , wherein said progestogenic component is administered in the same composition as the estetrol.
21 . The method of claim 16 , wherein said estetrol is estetrol monohydrate.
22 . The method of claim 16 , further comprising administering bazedoxifene.
23 . The method of claim 22 , wherein said bazedoxifene is administered in the same composition as the estetrol.
24 . A method of treating moderate to severe vasomotor symptoms (VMS) associated with menopause, comprising administering once daily to a woman with a uterus a composition comprising about 15 mg estetrol.
25 . The method of claim 24 , further comprising administering a progestogenic component.
26 . The method of claim 25 , wherein said progestogenic component is selected from drospirenone, progesterone, and dydrogesterone.
27 . The method of claim 25 , wherein said progestogenic component is progesterone and is administered at a daily dose of from 50 mg to 200 mg.
28 . The method of claim 25 , wherein said progestogenic component is administered in the same composition as the estetrol.
29 . The method of claim 24 , wherein said estetrol is estetrol monohydrate.
30 . The method of claim 24 , further comprising administering bazedoxifene.
31 . The method of claim 30 , wherein said bazedoxifene is administered in the same composition as the estetrol.
32 . A method of treating moderate to severe vasomotor symptoms (VMS) associated with menopause, comprising administering once daily to a woman without a uterus a composition comprising about 15 mg estetrol.
33 . The method of claim 32 , further comprising administering a progestogenic component.
34 . The method of claim 33 , wherein said progestogenic component is selected from drospirenone, progesterone, and dydrogesterone.
35 . The method of claim 33 , wherein said progestogenic component is progesterone and is administered at a daily dose of from 50 mg to 200 mg.
36 . The method of claim 33 , wherein said progestogenic component is administered in the same composition as the estetrol.
37 . The method of claim 32 , wherein said estetrol is estetrol monohydrate.
38 . The method of claim 32 , further comprising administering bazedoxifene.
39 . The method of claim 38 , wherein said bazedoxifene is administered in the same composition as the estetrol.